Lars Søndergaard has left his role as professor of cardiology at Rigshospitalet, Copenhagen University Hospital, (Copenhagen, Denmark) to take up a position as divisional vice president, medical affairs and chief medical officer, Structural Heart at Abbott.
Søndergaard, who has been a key figure among many of the leading trials of transcatheter aortic valve implantation (TAVI) over the last decade and a half, announced the career move in a post on his Linkedin profile.
“Thirty years after starting as a locum registrar at Rigshospitalet, I got a great opportunity to make an even broader impact on what it is all about—improving patient outcomes,” Søndergaard posted last week. “I appreciate the multidisciplinary collaboration, which is paramount for moving the field forward. [I am] proud to leave the hospital with a number of guidelines-changing achievements and great next generation teams to continue the journey.”
He subsequently posted that he would be joining Abbott’s structural heart business, overseeing a portfolio that includes devices for heart valve therapy, stroke prevention, and treatment of congenital heart disease. “I am excited to be part of the Abbott team as well as collaborating with peers on further development of patient treatment,” he wrote.
